US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

1.690 +0.010 (+0.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024 ↗
PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024 ↗
PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
News headline image
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
3 Biotech Stocks to Buy on the Dip: March 2024 ↗
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
News headline image
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
From Pyxis Oncology
Via GlobeNewswire
News headline image
Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
Shares of FedEx Corporation (NYSE: FDX) rose sharply in today’s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion 
Via Benzinga
News headline image
PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023 ↗
PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
From Pyxis Oncology
Via GlobeNewswire
News headline image
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
News headline image
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires ↗
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces $50 Million Private Placement
From Pyxis Oncology
Via GlobeNewswire
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalities 
From Pyxis Oncology
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >